The United States live biotherapeutic products (LBPs) market for inflammatory bowel disease (IBD) was valued at USD 0.42 billion in 2026. The market is projected to grow from USD 0.45 billion in 2026 to USD 0.81 billion by 2034, exhibiting a CAGR of approximately 8.9% during the forecast period.
Download FREE Sample Report:United States Live...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)